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A B S T R A C T   
To gain a better understanding of which pharmaceuticals could pose a risk to fish, 94 pharmaceuticals repre-
senting 23 classes were analyzed in blood plasma from wild bream, chub, and roach captured at 18 sites in 
Germany, the Czech Republic and the UK, respectively. Based on read across from humans, we evaluated the 
risks of pharmacological effects occurring in the fish for each measured pharmaceutical. Twenty-three com-
pounds were found in fish plasma, with the highest levels measured in chub from the Czech Republic. None of the 
German bream had detectable levels of pharmaceuticals, whereas roach from the Thames had mostly low con-
centrations. For two pharmaceuticals, four individual Czech fish had plasma concentrations higher than the 
concentrations reached in the blood of human patients taking the corresponding medication. For nine additional 
compounds, determined concentrations exceeded 10% of the corresponding human therapeutic plasma con-
centration in 12 fish. The majority of the pharmaceuticals where a clear risk for pharmacological effects was 
identified targets the central nervous system. These include e.g. flupentixol, haloperidol, and risperidone, all of 
which have the potential to affect fish behavior. In addition to identifying pharmaceuticals of environmental 
concern, the results emphasize the value of environmental monitoring of internal drug levels in aquatic wildlife, 
as well as the need for more research to establish concentration-response relationships.   
1. Introduction 
It is accepted that most pharmaceuticals are not completely metab-
olized in the body and many are incompletely removed in wastewater 
treatment plants (WWTP). Thus, they can be found in receiving waters 
around the world. Detected surface water concentrations of pharma-
ceuticals usually range from low µg L− 1 close to point sources down to 
low ng L− 1, with clear correlations to consumption volumes and pop-
ulations served by the relevant WWTP, the dilution factor and tech-
nologies used to treat the wastewater (Fatta-Kassinos et al., 2011; 
Hughes et al., 2013; Fick et al., 2017; Yang et al., 2017; Tran et al., 
2018). A range of environmental factors affecting in-stream primary 
degradation can also influence water concentrations of pharmaceuticals 
some of which have characteristic seasonal variations, e.g. temperature 
and the intensity of ultraviolet radiation. While concentrations are often 
low, many pharmaceuticals are highly potent and therefore may still 
exert pharmacological effects. Exposed wildlife, particularly verte-
brates, often have conserved drug targets with humans, including many 
receptors and enzymes. Such conservation provides a potential for 
pharmacological effects via high-affinity interactions with target mole-
cules in non-target species (Gunnarsson et al., 2008; Brown et al., 2014). 
Fish, in particular, have the potential to be affected by residual 
pharmaceuticals, since they are water respiring organisms and at the 
same time they share many of the drug targets with humans. It should be 
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emphasized that fish have a huge diversity in morphology, physiology 
and behavior and that inter- and intra-species specific uptake, bio-
accumulation and tissue partitioning of pharmaceuticals is poorly un-
derstood. Several studies have shown detectable levels of 
pharmaceuticals in fish collected from various types of surface waters e. 
g. (Ramirez et al., 2007; Schultz et al., 2011; Huerta et al., 2012, 2018; 
Subedi et al., 2012; Du et al., 2014; Tanoue et al., 2015; Grabicova et al., 
2017; Muir et al., 2017) and this literature was recently reviewed in 
Miller et al. (2018). 
Many of the studies that have analyzed pharmaceuticals in wild fish 
have focused on antidepressants, antibiotics, and anti-histamines, but 
pharmaceuticals from other classes have also been detected (Huerta 
et al., 2012; Zenker et al., 2014; Miller et al., 2018). Although freshwater 
organisms often contain higher concentrations of pharmaceuticals (due 
to less dilution and often closer vicinity to point sources and hence less 
time to degrade before exposure), pharmaceuticals have also been found 
in marine species living in coastal areas (Maruya et al., 2012; Gel-
sleichter and Szabo, 2013; Alvarez-Munoz et al., 2015; Lolić et al., 2015; 
Alygizakis et al., 2016; Moreno-González et al., 2016; Liu et al., 2018). 
Concentrations reported by authors referenced within this work in 
various tissues and/or plasma range from sub ng g− 1 (ng mL− 1 for 
plasma) up to >100 ng g− 1 (ng mL− 1 for plasma) expressed as either dry 
or wet weight (the difference between wet weight and dry weight con-
centrations in fish tissue is typically around a factor of four). 
Some studies have investigated concentrations in several tissues of 
the same individuals, such as blood plasma, muscle, liver, bile and brain 
(Brooks et al., 2005; Ramirez et al., 2009; Huerta et al., 2012; Brozinski 
et al., 2013; Grabicova et al., 2014, 2017; Tanoue et al., 2015). How they 
partition varies for different pharmaceuticals and their specific chemical 
properties, e.g. the highest levels of selective serotonin re-uptake in-
hibitors (SSRI) was shown in liver and brain tissues compared to muscle 
and plasma in three different species (Brooks et al., 2005; Ramirez et al., 
2007; Grabicova et al., 2014) while the opposite was shown for the 
antihypertension drug diltiazem (Ramirez et al., 2007). Some com-
pounds, e.g. sertraline, were not detected in plasma, while they were 
present in other organs (Grabicova et al., 2017). 
Blood plasma may not always contain the highest levels (compared 
to other organs) in exposed biota, however data on blood plasma levels 
in wildlife provides the possibility to make direct comparisons with the 
corresponding human therapeutic plasma concentrations (HTPCs) 
available for most drugs. This “Read-Across Hypothesis” suggests that 
since pharmaceuticals are designed to act at specific mammalian targets 
they may have effects in non-target organisms at similar plasma con-
centrations (Huggett et al., 2003). This hypothesis is only valid if drug 
targets are conserved between species, which has been shown to be the 
case for several drug targets in several fish species (Gunnarsson et al., 
2008; Rand-Weaver et al., 2013; Brown et al., 2014; Margiotta-Casaluci 
et al., 2014). It is, therefore, possible to calculate a concentration ratio 
(CR) between measured plasma levels and HTPCs that indicate the 
probability of a pharmacological effect in exposed biota. However, 
threshold effect levels for some compounds might differ between 
species. 
The aim of this study was to determine concentrations of 94 phar-
maceuticals in 110 plasma samples from fish caught at 18 sites in the UK, 
Germany and the Czech Republic, and identify the pharmaceuticals of 
most concern by comparison to human therapeutic levels (read-across). 
2. Materials and method 
2.1. Selection of pharmaceuticals included in the study 
Target pharmaceuticals were selected based on a combination of 
potency, physico-chemical properties and sales volume as has been 
described previously (Fick et al., 2010b). Additional criteria were 
availability of commercial reference standards and inclusion of as many 
therapeutic classes as possible. The final selection included 94 
pharmaceuticals from 23 classes (Supporting information, Table S1). 
2.2. Chemicals and reagents 
All of the reference pharmaceuticals standards were classified as 
analytical grade (>98%). Internal standards used were; 2H6 -amitrip-
tyline, 2H10-carbamazepine, 13C315N-ciprofloxacin, 13C2-ethinyl estra-
diol, 2H5-fluoxetine, 13C6-sulfamethoxazole, 13C2H3-tramadol and 13C3- 
trimethoprim, obtained from Cambridge Isotope Laboratories (Andover, 
MA, USA), 2H5-oxazepam, 2H4-risperidone, and 13C215N-tamoxifen, 
bought from Sigma-Aldrich (Steinheim, Germany) and 2H6-codeine, 
2H4-diclofenac, 2H4-flecainide, 2H3-ketoprofen, 13C32H3-naproxen 2H3- 
paracetamol purchased from CDN-Isotopes (Pointe-Claire, Quebec, 
Canada). LC/MS grade quality of methanol and acetonitrile were pur-
chased (Lichrosolv - hypergrade, Merck, Darmstadt, Germany) and pu-
rified water was prepared using a Milli-Q Advantage, ultrapure water 
system including an UV radiation source (Millipore, Billerica, USA). 
Formic acid (Sigma-Aldrich, Steinheim, Germany) was used to prepare 
the 0.1% mobile phases. 
2.3. Sampling and sampling locations 
Sampling locations were chosen to include both effluent dominated 
sites and less impacted sites. Samples were obtained from on-going na-
tional sampling campaigns in Germany, United Kingdom and the Czech 
Republic. Samples from each sampling site were analyzed within six 
months after sampling to avoid differences in storage time. Detailed 
characteristics of sampling locations with estimated dilution factors are 
given in Table 1. 
Germany; Representative bream (Abramis brama) plasma samples 
collected in 2007–2008 at 7 different German Environment Specimen 
Bank (GESB) sampling locations were provided from the GESB archive 
(n = 10, for each site). Sampling locations included 6 river sites located 
downstream from WWTP discharges along the Danube, Elbe, Mulde, 
Rhine, Saale and Saar rivers and Lake Belau, a reference lake site, which 
does not receive WWTP effluent. 
United Kingdom, Plasma samples from roach (Rutilius rutilus) (n = 30) 
were taken at ten particular sampling points along 25 km of the lower 
River Thames (between Marlow and Old Windsor) in September 2011. 
The Thames Basin upstream of Windsor (the most downstream fish 
sampling point) covers 7,046 km2 with a mean annual flow of 58 m3 s− 1 
receiving waste from an estimated 4.5 million people (Marsh, 2008). 
Major upstream cities include Reading, Oxford and Swindon. 
Czech Republic; Plasma samples from chub (Squalius cephalus) (n =
10, at one site), were collected in 2012. Sampling location was in the 
Bezdrevský stream, a small tributary of Vltava River in the South 
Bohemia region with a total catchment area of 340 km2. No discharges 
from hospitals or manufacturing sites for pharmaceuticals are present 
within the catchment area. This locality represents a typical regional 
scenario where effluent from WWTP is discharged into a small recipient 
watercourse. 
2.4. Sample pretreatment 
Five nanograms of each internal surrogate standard and methanol 
with 0.1% formic acid (100 µL) were added to each plasma sample (100 
µL) which was then frozen at − 18 ◦C overnight. Samples were thawed, 
200 µL of water (with 0.1% formic acid) were added and the samples 
were centrifuged at 14,000 revolutions per minute for 10 min. 
2.5. Analytical system 
The autosampler used in this study was a PAL HTC autosampler with 
cooled sample trays (CTC Analytics AG, Zwingen, Switzerland). Accela 
pump, mass analyzer (TSQ Quantum Ultra EMR, triple stage quadrupole 
MS/MS) and software (Xcalibur) were made by Thermo Fisher Scientific 
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(San Jose, CA, USA). Heated electrospray (HESI) in positive ion mode 
was used for ionization of the pharmaceuticals. Specific details related to 
the determination of the pharmaceuticals including HESI ionizations, 
polarities, precursor/product ions, collision energies, tube lens values, 
etc. have been described elsewhere (Grabic et al., 2012). 
2.6. Quality assurance and quality control 
Two MS/MS transitions were used for positive identifications of 
analytes with the criterion that the ratio between the transitions was not 
allowed to deviate more than +/− 30% from the ratio in the corre-
sponding calibration standard. Retention times for all analytes also had 
to be within +/− 2.5% of the retention time in the corresponding cali-
bration standard. Together, this gave four identification points (the 
highest possible number), as described in the Commission Decision 
2002/657/EC (European Commission, 2002) concerning the perfor-
mance of analytical methods and the interpretation of results. The limit 
of quantification (LOQ) was determined from standard curves based on 
repeated measurements of low level spiked plasma samples, and the 
lowest point in the standard curve that had a signal/noise ratio of at least 
10 was considered to be equal to the LOQ. A seven-point matrix adjusted 
calibration curve over the range of 0.05–100 ng mL− 1 was used for 
linearity evaluation and quantification. Carry-over effects were evalu-
ated by injecting standards at 100 ng mL− 1 followed by two mobile 
phase blanks. Several instrumental and field blanks were included in the 
analytical runs. 
3. Results 
No carry-over effects were observed, no pharmaceuticals were 
detected in the instrumental or field blanks and R2 values were above 
0.99 for all calibration curves in the given concentration ranges. Abso-
lute recoveries in fish plasma are shown in Table S1, Supporting 
Information. 
A total of 23 different pharmaceuticals were detected in at least one 
fish sample. No pharmaceuticals were found in the 70 bream plasma 
samples from Germany, while a total of 12 pharmaceuticals were 
observed in 22 out of 30 examined roach from River Thames (UK) and a 
total of 18 pharmaceuticals were found in 9 out of 10 chub from the 
Czech Republic. 
Flecainide was the most frequently detected pharmaceutical in the 
UK plasma samples (15/30), followed by carbamazepine (7/30). Fle-
cainide is used to treat patients with a high heart rate and carbamaze-
pine is a commonly used anti-convulsant. Other detected 
pharmaceuticals were found in single individuals, usually at concen-
trations close to the LOQ. All determined concentrations in each indi-
vidual fish are presented in Table S2, Supporting information. 
In case of the Bezdrevský stream (CZ), 8 out of the 18 detected 
pharmaceuticals (bupropion, clarithromycin, clomipramine, diphenhy-
dramine, haloperidol, oxazepam, risperidone, venlafaxine) were found 
at concentrations above the LOQ in at least 30% of the sampled in-
dividuals, but carbamazepine and flecainide were not detected in Czech 
fish plasma. The most consistent presence in Czech fish was risperidone 
(9/10), an anti-psychotic drug, followed by the antidepressant bupro-
pion (4/10) and the antibiotic clarithromycin (4/10). All detected 
concentrations in each individual fish are presented in Table S3, Sup-
porting information. 
Two pharmaceuticals, the anti-psychotic drugs risperidone and/or 
flupentixol were found in fish plasma at levels higher than the HTPC, i.e. 
fish plasma concentration/HTPC (CR) > 1, representing high risk to 
induce pharmacological effects, both in samples from the Czech Re-
public. In the case of risperidone, three of nine positive samples excee-
ded this threshold. Flupentixol concentrations were quantifiable in only 
two samples due to relatively high LOQ (higher than HTPC), but con-
centrations in these two positive samples were more than ten times 
higher than the HTPC. Nine more pharmaceuticals had a CR > 0.1 in 12 
individual fish from the UK and Czech Republic, which could be 
considered to reflect a moderate risk of inducing pharmacological effect, 
however the mean values usually were below this threshold (Tables 2 
and 3). These nine pharmaceuticals were the antidepressants bupropion, 
clomipramine and mianserin; the neuroleptic haloperidol; the anxiolytic 
drug oxazepam; the antibiotic azithromycin; the antidiabetic drug 
repaglinide; alfuzosin, a drug for treatment of benign prostatic hyper-
plasia and the antifungal clotrimazole. The majority (6/10) of Czech fish 
had more than one pharmaceutical with a CR > 0.1 or/and a CR > 1 (up 
to four compounds) in their plasma, indicating the possibility of un-
known combinatory effects in these individuals. 
4. Discussion 
In this study we have analyzed a large set of pharmaceuticals in 
blood plasma of wild fish from three European countries. By comparing 
detected levels in the fish to those observed in human blood plasma 
Table 1 
Characteristics of the sampling sites with estimated dilution factors.  
Sampling site Date MAF1 Significant 
WWTPs2 
DSL3 EI4 EDL5 
(m3 
s− 1) 
(km) 
Bezdrevský 
stream, 
Netolice 
(Cz) 
2/ 
2012 
0.4826 Netolice 0 2 
700 
48x 
Lhenice 15 1 
800 
River Saar, 
Güdingen 
(G1) 
7/ 
2008 
60 Brebach 0 135 
000 
131x 
Saargemünd 11 61 
500 
River Rhine, 
Bimmen 
(G2) 
7/ 
2008 
2000 Salmorth 7 40 
833 
3 
717x 
Emmerich 14 126 
736 
Kalkar-Hönnepel 23 38 
401 
Xanten-Vynen 34 606 
Xanten-Lüttingen 41 5 
753 
Wesel 50 19 
900 
River Elbe, 
Blankenese 
(G3) 
8/ 
2008 
800 Köhlbrandhöft/ 
Dradenau 
4 2 
900 
000 
117x 
Geesthacht 
Düneberg 
43 60 
000 
River Saale, 
Wettin (G4) 
8/ 
2008 
115 Halle-Nord 15 300 
000 
54x 
Leipzig-Rosental 64 628 
000 
River Mulde, 
Dessau (G5) 
8/ 
2008 
64 Bitterfeld-Wolfen 37 422 
000 
65x 
River Danube, 
Jochenstein 
(G6) 
9/ 
2008 
1000 Obernzell 0 ≈ 10 
000 
3 
597x 
Thyrnau 6 ≈ 10 
000 
Achleiten 8 ≈
100 
000 
Lake Belau 
(G7) 
9/ 
2008 
reference site, no WWTP effluent 
River Thames 
(UK) 
9/ 
2011 
58 Whole catchment 
upstream of 
Windsor  
4 
500 
000 
10x 
1Mean annual flow at the sampling location; 2Known WWTP effluent discharges 
upstream of sampling location - the information provided does not include all 
possible sources of pharmaceutical pollution, e.g. distant sources (>100 km); 
3Distance of WWTP discharge from sampling location; 4equivalent inhabitants 
served by WWTP; 5N fold dilution of sum of WWTP effluents at the sampling 
location using an assumed per capita waste discharge of 200 L/cap/d. Charac-
teristics of German sampling sites and WWTPs were adopted from Subedi et al. 
(2012); 6actual flow at the date of sampling was estimated to be 0.05 m3 s− 1. 
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during therapy, we have identified a range of drugs, in particular 
neuroactive ones, at levels that would be expected to cause pharmaco-
logical effects in wild fish. For two pharmaceuticals, blood levels in a 
few individual fish exceeded the levels achieved in blood during therapy 
in humans at the Czech locality, while nine exceeded a tenth of those 
concentrations in Czech and UK fish. For the majority of these drugs, the 
risk was only observed at the level of single individuals, but for azi-
thromycin, flupentixol, haloperidol, and risperidone, the threshold was 
exceeded even at the population level (mean value), again only at the 
Czech site. Previous research on the risks pharmaceuticals pose in the 
environment has primarily not been guided by a read-across approach, 
but has more often been based on comparing predicted or measured 
exposure via surface water to effect data from controlled exposure 
studies. We think the read-across approach has a value in identifying 
pharmaceuticals of environmental concern, but results should be fol-
lowed up by controlled effect studies. More field studies assessing 
exposure would be valuable to judge how representative our results are. 
Investigating how abiotic factors (including temperature) and the choice 
of indicator species might affect plasma levels in wild fish would further 
increase the interpretability of read-across studies in general. 
In our previous research, a number of compounds were measured in 
various fish tissues that were not detected in plasma (Grabicova et al., 
2017). Additionally, for many of the pharmaceuticals highlighted here, 
ecotoxicity data with relevance for their specific mode of action is 
lacking or very limited. We therefore suggest an increased focus on these 
drugs in order to better understand their exposure potential and impact 
on aquatic wildlife. The levels of pharmaceuticals varied between spe-
cies and sites in a way we cannot fully explain. Hence, there is also a 
need to better understand the factors that govern e.g. bioconcentration, 
both in order to effectively design environmental monitoring ap-
proaches and for pointing out species and populations that are at 
increased risks to be affected by residual drugs. 
Table 2 
Detection frequency, average and concentration range, and risk assessment of analyzed pharmaceuticals in fish plasma samples (n = 10) from the Bezdrevský stream, 
Czech Republic.  
Name D.F.a Plasma concentration in ng mL− 1 HTPCb  Estimated risk c 
mean ± SD (min - max) median ng mL− 1  (min - max) 
Azithromycin 1/10 4.15 ± 5.218 (<5–19) <LOQ 40 ** (0.063–0.475) 
Biperiden 1/10 0.06 ± 0.019 (<0.1–0.11) <LOQ 50 * (0.001–0.002) 
Bisoprolol 1/10 0.06 ± 0.019 (<0.1–0.11) <LOQ 10 * (0.005–0.011) 
Bupropion 4/10 0.28 ± 0.441 (<0.1–1.4) <LOQ 10 * (0.005–0.14) 
Clarithromycin 4/10 2.44 ± 3.4 (<1–11) <LOQ 200 * (0.003–0.055) 
Clomipramine 3/10 1.8 ± 3.997 (<0.5–13) <LOQ 20 * (0.013–0.65) 
Clotrimazole 1/10 0.73 ± 0.727 (<1–2.8) <LOQ 34 * (0.015–0.082) 
Desloratadine 1/10 0.32 ± 0.206 (<0.5–0.90) <LOQ 10 * (0.025–0.09) 
Diphenhydramine 3/10 0.05 ± 0.053 (<0.05–0.19) <LOQ 50 * (0.001–0.004) 
Flecainide 1/10 0.06 ± 0.032 (<0.1–0.15) <LOQ 200 * (<0.001–0.001) 
Flupentixol 2/10 3.72 ± 3.031 (<5–12) <LOQ 0.5 *** (5–24) 
Haloperidol 3/10 0.14 ± 0.18 (<0.1–0.60) <LOQ 1 ** (0.05–0.6) 
Hydroxyzine 1/10 0.28 ± 0.089 (<0.5–0.53) <LOQ 50 * (0.005–0.011) 
Oxazepam 3/10 6.95 ± 7.823 (<5–25) <LOQ 200 * (0.013–0.125) 
Repaglinide 1/10 0.2 ± 0.561 (<0.05–1.8) <LOQ 15 * (0.002–0.12) 
Risperidone 9/10 4.41 ± 3.720 (<0.1–10) 4.70 6 ** (0.008–1.667) 
Sotalol 2/10 0.45 ± 0.496 (<0.5–1.8) <LOQ 500 * (0.001–0.004) 
Venlafaxine 3/10 3.26 ± 5.86 (<0.5–11) <LOQ 200 * (0.001–0.085)  
a Detection frequency. 
b Human therapeutic plasma concentrations (for more information see Table S4, Supporting information). 
c Risk of inducing the therapeutic effect in fish; ***, high risk (mean concentration exceeding the HTPC); **, moderate risk (mean concentration below HTPC, but 
exceeding 10% of HTPC); *, low risk (mean concentration below 10% of HTPC). To calculate mean concentration and mean risk quotient, samples below LOQ were 
replaced with ½ of LOQ value. 
Table 3 
Detection frequency, average and concentration range, and risk assessment of analyzed pharmaceuticals in fish plasma samples (n = 30) from 10 sampling sites along a 
25 km stretch of the River Thames, UK.  
Name D.F.a Plasma concentration in ng mL− 1 HTPCb  Estimated riskc 
Mean ± SD (min - max) Median ng mL− 1  (min - max) 
Alfuzosin 1/30 0.06 ± 0.051 (<0.1–0.33) <LOQ 3 * (0.017–0.11) 
Bupropion 1/30 0.06 ± 0.064 (<0.1–0.4) <LOQ 10 * (0.005–0.04) 
Carbamazepine 7/30 1.09 ± 1.229 (<1–4.4) <LOQ 2000 * (<0.000–0.002) 
Clomipramine 2/30 0.33 ± 0.366 (<0.5–2.2) <LOQ 20 * (0.013–0.11) 
Clotrimazole 2/30 0.66 ± 0.613 (<1–3.4) <LOQ 34 * (0.015–0.1) 
Desloratadine 1/30 0.33 ± 0.429 (<0.5–2.6) <LOQ 10 * (0.025–0.26) 
Flecainide 15/30 0.43 ± 0.714 (<0.1–2.8) 0.06 200 * (<0.000–0.014) 
Mianserin 1/30 0.57 ± 0.365 (<1–2.5) <LOQ 10 * (0.05–0.25) 
Miconazole 2/30 0.93 ± 2.108 (<1–12) <LOQ 250 * (0.002–0.048) 
Pizotifen 1/30 0.07 ± 0.091 (<0.1–0.55) <LOQ 7 * (0.007–0.079) 
Repaglinide 2/30 0.09 ± 0.291 (<0.05–1.6) <LOQ 15 * (0.002–0.107) 
Risperidone 2/30 0.07 ± 0.089 (<0.1–0.54) <LOQ 6 * (0.008–0.09)  
a Detection frequency. 
b Human therapeutic plasma concentrations (for more information see Table S4, Supporting information). 
c Risk of inducing the therapeutic effect in fish; ***, high risk (mean concentration exceeding the HTPC); **, moderate risk (mean concentration below HTPC, but 
exceeding 10% of HTPC); *, low risk (mean concentration below 10% of HTPC). To calculate mean concentration and mean risk quotient, samples below LOQ were 
replaced with ½ of LOQ value. 
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4.1. Possible ecological consequences of analyzed pharmaceuticals in fish 
plasma 
Flupentixol, haloperidol and risperidone represent neuroleptics that 
have antipsychotic effects in humans likely caused by dopamine (D2) 
and/or serotonin 2A (5-HT2A) receptor antagonism. As D2 and 5-HT2A 
receptors represent evolutionary highly conserved mechanisms (Gun-
narsson et al., 2008), adverse effects of neuroleptics including behav-
ioral changes may be expected in some aquatic animals as well. 
Haloperidol and risperidone have previously been found in wild fish 
(Fick et al., 2010a; Tanoue et al., 2015; Grabicova et al., 2017). A 
German research group has published a series of papers, reporting ef-
fects of very low levels (down to 0.3 ng L− 1) of risperidone on fish 
(Idalencio et al., 2015; Kalichak et al., 2017). Moreover, findings of 
Kalichak et al. (2019) suggest that some of these effects might be irre-
versible and even transgenerational as they were observed in adult fish 
that were only exposed to risperidone during early larval stage and in 
their F1 generation. In case of adult fish, however, the only significant 
effects were observed in prey-predator tests and these did not follow any 
dose-response relationships. More studies are thus warranted to clarify 
the potency and actions of risperidone in fish, and hence to understand 
the environmental risks associated with this drug, once exposure is taken 
into account. For haloperidol and flupentixol, we are not aware of any 
studies in fish that are likely to reflect their specific mode of action. 
The antidepressants mianserin, bupropion, and clomipramine were 
all found in plasma of a few individual fish at concentrations indicating a 
moderate risk. Mianserin interacts with serotonin, histamine and 
κ-opioid receptors and inhibits the reuptake of norepinephrine. Bupro-
pion is a norepinephrine–dopamine reuptake inhibitor (NDRI) and a 
nicotinic receptor antagonist. Clomipramine inhibits norepinephrine 
reuptake and, at the same time, acts as an antagonist on histamine, 
acetylcholine, and adrenergic receptors. These three compounds have 
been found in wild fish in other studies (Schultz et al., 2010; Arnnok 
et al., 2017; Grabicova et al., 2017). While there is a rather large liter-
ature on the ecotoxicity of selective serotonin reuptake inhibitors, these 
antidepressant have received considerably less attention, particularly 
with regards to effects of realistic (ng L− 1) levels on fish behavior. 
Oxazepam, an anxiolytic that has frequently been found in surface 
waters (Fick et al., 2017), was determined in the plasma of three indi-
vidual fish from the Czech sampling site in concentrations up to 25 ng 
mL− 1. As the HTPC for oxazepam is 200 ng mL− 1, the higher concen-
trations represent a moderate risk. However, some previous studies re-
ported effects on behavior in fish having the internal oxazepam 
concentration between 6.6 and 36 ng g− 1 in muscle (Brodin et al., 2013) 
and 30 ng mL− 1 (mean, N = 32) in plasma (Huerta et al., 2016). These 
findings might indicate higher sensitivity of certain vertebrates to spe-
cific pharmaceuticals compared to human therapeutic plasma levels. 
4.2. Variability of plasma concentrations 
There were remarkable differences in the levels of pharmaceuticals 
detected in the German, UK, and Czech fish. Reasons explaining the 
large discrepancies could include regional differences in use, differences 
in removal efficiencies between WWTPs, different abilities of the three 
fish species to bioconcentrate the drugs (in turn affected by e.g. foraging 
behaviors, species-specific metabolism etc.), potential differences in 
handling fish before sampling, and, importantly, the nature and dilution 
of treated wastewater effluents at the investigated sites. Here we discuss 
some of these potential explanations. 
Subedi et al. (2012) studied uptake in fish tissue samples from the 
same species (bream) from the same locations in Germany, taken at the 
same time as the plasma samples analyzed in the present study. These 
authors analyzed 15 pharmaceuticals but only detected one parental 
compound (diphenhydramine) and one metabolite (desmethylsertra-
line) in the range of 0.04–0.07 ng g− 1 (ww) and 1.65–3.28 ng g− 1 (ww), 
respectively. Although we did not find diphenhydramine in any of the 
analyzed bream plasma samples from Germany, the non-detect for all 
other analyzed drugs in both studies is largely in agreement with the 
lack of detections reported in our study. 
It is important to remember pharmaceuticals do not behave as 
persistent organic pollutants or as heavy metals, which accumulate in 
biota over time. Pharmaceuticals are designed by drug companies to be 
ultimately metabolized or/and excreted by their human patients and it is 
not unreasonable to expect this to occur also in most other vertebrates. 
Thus, it seems right to assume that the detections in plasma found here 
represent the recent experience of these fish. The most plausible 
explanation behind the varying levels of pharmaceuticals found at the 
different sites then would be that the level of exposure is likely to differ, 
although it may not explain the entire difference found. Dilution of 
WWTP discharges (Table 1) would explain the lack of detections at some 
German sites (G1, G2, G3, G6, and reference G7), where dilution factors 
were estimated to be >100 fold, but not in the other two. Sampling sites 
located at Saale (G4) and Mulde (G5) Rivers were characterized with a 
similar dilution factors as the Bezdrevský stream (Cz), which indicates 
that other factors may be pivotal for the absence of pharmaceuticals in 
fish plasma from these sites. Nevertheless, it should be noted that dilu-
tion factors were calculated from median values of flow rates at the 
sampling sites, which does not need to correspond to the actual situation 
at the time of sampling. For instance, at Czech site the actual flow was 
estimated to be about 10% of its median value, which means only a tenth 
of the median dilution of WWTP effluent at the date of sampling. It was 
shown for some pharmaceuticals that steady state can be reached rela-
tively quickly in fish, e.g. 2 days in case of certain NSAIDs (Brown et al, 
2007), similar in case of benzodiazepine drug temazepam (McCallum et 
al, 2019). In line with these findings, we suppose that even short-term 
exposure to elevated concentrations of detected pharmaceuticals due 
to very low dilution of WWTPs effluent at Czech site could lead to rapid 
increase in concentrations of these compounds in fish plasma. 
As we do not have exact data about consumption of individual 
compounds included in this study in different regions, it is hard to es-
timate to which extent this would affect the plasma concentrations. 
Some information can be obtained from OECD databases, e.g. for all 
antidepressants, the defined daily dose per 1000 inhabitants day− 1 was 
38, 42, and 70 in the Czech Republic, Germany, and UK respective in 
2011 (OECD, 2011). Still, antidepressants were more frequent in plasma 
of Czech fish compare to UK. 
Different foraging behavior between bream, roach, and chub could 
be a partial explanation. It needs to be emphasized that respiration is 
known to be the main pathway of most pharmaceuticals exposure in fish, 
but feeding preferences might contribute to some extent particularly for 
hydrophobic compounds, which adsorb strongly to solids. Several 
studies have also shown a wide variation in the uptake and depuration of 
pharmaceuticals between different species (Miller et al., 2018). Unfor-
tunately, there is a lack of data regarding the pharmacokinetics of these 
pharmaceuticals in the species included in our study. In the very recent 
investigation of Malev et al. (2020), 87 pharmaceuticals were detected 
in plasma of chub sampled in the Sava River (Croatia) compared to 60 
and 54 in barbel (Barbus barbus) and spirlin (Alburnoides bipunctatus), 
indicating species specific differences in uptake. 
Contrary to the German and UK sites, fish from Czech Republic were 
caught and sampled in winter (February). Higher concentrations of 
pharmaceuticals are likely to be expected in the recipients of WWTPs 
due to their lower removal efficiency during the cold periods (Golovko 
et al., 2014). Moreover, estimated flow rate at the time of sampling was 
about 10% of the annual median at Czech sampling site, which could 
significantly affect the dilution of WWTP effluents. The recent study of 
Grabicova et al. (2020) investigated psychoactive compounds in water 
and fish tissues at 10 Czech localities including the Bezdrevský stream. 
Only sertraline was found in fish brain from this locality, which might 
indicate different dilution due to higher flow rate at the time of sampling 
or/and possible improvements in technology of local WWTP. The site 
expressed intermediate level of contamination from 10 investigated sites 
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based on the number of compounds and their concentrations present in 
water and in fish tissues. However, concentrations in fish blood plasma 
were not investigated. 
It has been hypothesized that co-exposure to multiple chemicals/ 
pharmaceuticals could enhance bioconcentration, as suggested by a 
meta-analyses of levels of non-steroidal anti-inflammatory drugs in fish 
(Cuklev et al., 2012). Fish exposed to complex sewage effluent had 
higher levels of e.g. ketoprofen than fish exposed to similar levels of 
ketoprofen in clean water. Although still largely a speculation, this 
phenomenon could be due to saturation of detoxifying systems in the 
fish. Such a mechanism would be characterized by positive feedback (i.e. 
given that a certain exposure threshold is met, internal exposure will 
increase more rapidly). The further implications of this would be quite 
profound, as we then would have to assess risks with pharmaceuticals in 
the light of all other chemicals present. This, again, speaks in favor of a 
field-based approach as taken here. 
5. Conclusions 
When trying to identify pharmaceuticals with increased risks to 
affect wild fish, we show that a strategy that takes advantage of the 
drugs inherent biological potency combined with actual levels found in 
wild fish represents a promising approach. Applying read-across directly 
on analyzed, rather than theoretically derived, plasma levels from wild 
fish could help to reduce uncertainties of read-across studies concerning 
estimates of external exposure (via e.g. sales, removal in sewage treat-
ment plants, environmental fate or direct analyses of water) and bio-
concentration factors, which in the fish plasma model is only driven by 
lipophilicity. Furthermore, analyzing blood plasma samples does not 
necessarily mean that the studied fish need to be killed. Thus, this 
approach also allows studies of e.g. threatened fish populations and/or 
allows larger populations to be sampled to obtain reliable data. Never-
theless, additional research is necessary to reveal how species-specific 
differences in physiology, temperature, and co-exposure to other 
chemicals affect the pharmaceutical concentrations in fish plasma, 
which might help explain the high variability in plasma concentrations 
observed for some drugs in this study. 
We show that wild fish in certain European watercourses might be 
exposed to some pharmaceuticals at concentrations expected to affect 
their physiology. Many or even most of the pharmaceuticals found are 
not well studied in terms of ecotoxicity. Hence, more research is needed 
to establish dose–response relationships for these drugs in fish, and 
possibly also mitigations to reduce exposure. The majority of the phar-
maceuticals presenting moderate or high risk in this study were neuro-
active compounds characteristic with mid-range lipophilicity (log P), 
with a potential to alter natural fish behavior. Moreover, six of ten fish 
from the Czech site were facing a mixture of compounds at risk con-
centrations, which emphasize the need to study their combinatory ef-
fects as well. 
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Lolić, A., Paíga, P., Santos, L.H.M.L., Ramos, S., Correia, M., Delerue-Matos, C., 2015. 
Assessment of non-steroidal anti-inflammatory and analgesic pharmaceuticals in 
seawaters of North of Portugal: Occurrence and environmental risk. Sci. Total 
Environ. 508, 240–250. 
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